We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
- Authors
Maeda, Shimpei; Motoi, Fuyuhiko; Onogawa, Tohru; Morikawa, Takanori; Shigeru, Ottomo; Sakata, Naoaki; Takadate, Tatsuyuki; Naitoh, Takeshi; Rikiyama, Toshiki; Katayose, Yu; Egawa, Shinichi; Unno, Michiaki
- Abstract
Background: We evaluated the efficacy and feasibility of paclitaxel in patients with gemcitabine-refractory pancreatic cancer. We also evaluated the correlation between tumor marker decline and response rate. Methods: Thirty patients histologically diagnosed with pancreatic cancer who had undergone paclitaxel treatment as salvage chemotherapy were retrospectively analyzed. Paclitaxel treatment was performed with 80 mg/(m week) for 3 weeks followed by 1 week rest, and this was continued until failure. Tumor marker response was evaluated by measuring levels of carbohydrate antigen 19-9, carcinoembryonic antigen, and DUPAN-2 monthly. Results: In total, 272 weekly paclitaxel treatments were performed. The median number of treatments per patient was 8 (range 1-22). The median overall survival from the start of paclitaxel treatment was 6.7 months (range 1.2-18.8). The response rate was 10% (3/30 patients) and the disease control rate was 46.7% (14/30 patients). Although grade 3 and 4 hematological and non-hematological toxicities were seen in 7 and 6 patients, respectively, adverse events were managed by conservative treatment. We found a significant correlation between the disease control rate and tumor marker decline within 2 months of paclitaxel treatment ( P = 0.01). Patients with tumor marker decline tended to survive longer. Conclusion: Weekly administration of paclitaxel in patients with gemcitabine-refractory pancreatic cancer seems to be well tolerated and can be effective. Paclitaxel treatment should be considered as salvage chemotherapy after gemcitabine failure in patients with good performance status.
- Subjects
PACLITAXEL; CANCER chemotherapy; PANCREATIC cancer; DRUG efficacy; TUMOR markers; RETROSPECTIVE studies; FEASIBILITY studies
- Publication
International Journal of Clinical Oncology, 2011, Vol 16, Issue 5, p539
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-011-0220-8